Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Cartesian Therapeutics Inc (Cartesian), formerly Selecta Biosciences Inc, is a clinical-stage biotechnology company. It offers a proprietary technology and manufacturing platform, RNA Armory, which is designed to develop mRNA cell therapies for the treatment of autoimmune diseases. The company’s pipeline products include Descartes-08, Descartes-15 and Descartes-33. Its lead product Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen, which treats myasthenia gravis and systemic lupus erythematosus, other autoimmune diseases; Descartes-15 for autoimmune diseases and myeloma and Descartes-33, which is in preclinical development targets autoimmune diseases. Cartesian is headquartered in Gaithersburg, Maryland, the US.
Headquarters
United States of America
Address
704 Quince Orchard Road, Gaithersburg, Maryland, 20878
Website
www.cartesiantherapeutics.com
Telephone
1 617 9231400
No of Employees
38
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RNAC (NASD)
Revenue (2022)
$26.0M
-76.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-721%
(2022 vs 2021)
Market Cap*
$468.8M
Net Profit Margin (2022)
XYZ
-2,745.3%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | RNA Armory |
| Descartes-08: Myasthenia Gravis, Systemic Lupus Erythematosus and other Autoimmune Diseases | |
| Descartes-15: Myeloma and Autoimmune Diseases | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In November, the company merged with Cartesian Therapeutics, Inc. |
| 2023 | Contracts/Agreements | In January, the company and Astellas Pharm aannounced an exclusive licensing and development agreement for IdeXork. |
| 2018 | Contracts/Agreements | In August, the company leveraged Oracles's NetSuite to manage financial, accounting, and project management processes with one unified system. |
Competitor Comparison
| Key Parameters | Cartesian Therapeutics Inc | Johnson & Johnson | Novartis AG | AstraZeneca Plc | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United Kingdom | United States of America |
| City | Gaithersburg | New Brunswick | Basel | Cambridge | Princeton |
| State/Province | Maryland | New Jersey | - | England | New Jersey |
| No. of Employees | 38 | 131,900 | 76,057 | 89,900 | 34,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Singer, MD, PhD | Chairman; Chairman - Chief Strategy Officer | Executive Board | 2024 | 50 |
| Carsten Brunn, PhD | Director; President; Chief Executive Officer | Executive Board | 2018 | 53 |
| Blaine Davis | Chief Financial Officer | Senior Management | 2022 | 50 |
| Metin Kurtoglu, MD, PhD | Chief Operating Officer | Senior Management | - | 45 |
| Milos Miljkovic, MD, PhD | Chief Medical Officer | Senior Management | 2021 | 40 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer